Abstract
Purpose: To compare nicardipine (NCR) and prostaglandin E1 (PGE1) for portal venous contrast enhancement on indirect portography in a retrospective study.
Methods: One milligram of NCR, a calcium antagonist, was injected into the superior mesenteric artery just prior to portography in 18 patients who had undergone otherwise identical portography using 20 μg PGE136-279 (mean 133) days before. All 18 patients had liver tumors and showed no changes in portal vein status in the interim.
Results: Using conventional film/screen angiography, NCR provided equally good portograms as PGE1 with respect to image density and image contrast. Systemic effects on blood pressure and heart rate were minimal and no other side effects were observed with NCR.
Conclusion: NCR is an inexpensive drug and is expected to provide well-contrasted, indirect portograms on conventional film/screen ansiography
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Takenaka T, Usuda S, Nomura T, Maeno H, Sado T (1976) Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-l,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93). Arzneimittelforschung 26:2172–2192
Davis LJ, Anderson JH, Wallace S, Gianturco C, Jacobson ED (1975) The use of prostagiandin E, to enhance the angiographic visualization of the splanchnic circulation. Radiology 114:281–286
Cho KJ, Chuang VP, Reuter SR(1975) Prostagiandin E1 as a pharmacoangiographic agent for arterial portography. Radiology 116:207–209
Jonsson K, Wallace S, Jacobson ED, Anderson JH, Zornoza J, Granmaye M(1977) The use of prostagiandin E1 for enhanced visualization of the splanchnic circulation. Radiology 125:373 -378
Clark RA, Colley DP, Jacobson ED, Herman R, Tyler G, Stahl D (1980) Superior mesenteric angiography and blood flow measurement following intra-arterial injection of prostagiandin E1. Radiology 134:327–333
Gustafson T, Hedner P, Ingelmansson S (1982) Prostagiandin E1 effect on human splanchnic circulation at different dose levels. Invest Radiol 17:249–253
Ito T, Itoshima T, Ukida M, Kiyotoshi S, Kawaguchi K, Ogawa H, Hattori S, Kitadai M, Nagashima H (1982) Enhanced visualization of the portal vein system in superior mesenteric arterial portography using prostaslandin E1. Acta Med Okayama 36:291–297
Inoue Y, Nakamura H, Ogura Y, Yamasaki K (1993) Transarterial portography via superior mesenteric artery using nicardipine. Rinsho Hoshasen 38:341–344(In Japanese, English abstract)
Yamamoto M, Ohta T, Toda N (1983) Mechanisms of relaxant action of nicardipine, a new Ca++-antagonist, on isolated dog cerebral and mesenteric arteries. Stroke 14:270–275
Campbell BC, Kelman AW, Hills WS (1985) Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects. Br J Clin Pharmacol 20(suppl):55S-61S
Rousseau MF, Etienne J, Van Mechelen H, Veriter C, Pouleur H (1984) Haemodynamic and cardiac effects of nicardipine in patients with coronary artery disease. J Cardiovasc Pharmacol 6:833–839
Lambert CR, Hill JA, Nichols WW, Feldman RL, Pepine CJ (1985) Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 55:652–656
Silke B, Verma SR, Hafizullah M, Reynolds G, Frais MA, Jackson NC, Taylor SH (1984) Haemodynamic effects of nicardipine in acute myocardial infarction. Postgrad Med J 60(suppl 4):29–34
Seki T, Takenaka T (1977) Pharmacological evaluation of YC-93, a new vasodilator, in healthy volunteers. Int J Clin Pharmacol Biopharm 15:267–274
Takenaka T, Handa J (1979) Cerebrovascular effects of YC-93, a new vasodilator, in dogs, monkeys and human patients. Int J Clin Pharmacol Biopharm 17:1–11
Baba T, Boku A, Ishizaki T, Sone K, Takebe K(1986) Renal effects of nicardipine in patients with mild-to-moderate essential hypertension. Am Heart J 111:552–557
Baba T, Ishizaki T, Ido Y, Aoyagi K, Murabayashi S, Takebe K (1986) Renal effects of nicardipine, a calcium entry blocker, in hypertensive type II diabetic patients with nephropathy. Diabetes 35:1206–1214
Higuchi S, Shiobara Y (1980) Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 6:447–454
Rossi P, Simonetti G, Passariello R, Tempesta P, Pesce B, Pavone P, Castrucci M (1985) Digital celiac angiography. Radiology 154:229–231
Foley WD, Stewart ET, Milbrath JR, SanDretto M, Milde M (1983) Digital subtraction angiography of the portal venous system. AJRl40:497–499
Yashiro N, Ohtomo K, Furui S, Kokubo T, Irai Y, Iio M(1984) The role of intraarterial digital subtraction arteriography in visceral angiography. Nippon Acta Radiologica 44:1366–1373 (In Japanese, English abstract)
Michels NA (1955) Blood supply and anatomy of the upper abdominal organs. JB Lippincott, Philadelphia, pp 152-154
Soyer P, Lacheheb D, Levesque M (1993) CT arterial portography of the abdomen: Effect of injecting papaverine into the mesenteric artery on hepatic contrast enhancement. AJR 160:1213–1215
Graf O, Dock WL Lammer J, Thurnher S, Eibenberger KL, Wilding R, Niederle B, Lang EK, Lechner G (1994) Determination of optimal time window for liver scanning with CT during arterial portography. Radiology 190:43–47
Redman HC, Reuter SR, Miller VVJ(1969) improvement of superior mesenteric and portal vein visualization with tolazoline. Invest Radiol 4:24–27
Widrich WC, Nordahl DL, Robbins AH (1974) Contrast enhancement of the mesenteric and portal veins using intraarterial papaverine. AJR 121:374–379
Liu LC, Wu CC Liu LH, Chiang CP, Huang CH, Chou YH, Tan LB (1991) Comparison of the effects of papaverine versus prostaglandin E1 on penile blood flow by color duplex sonography. Eur Urol 19:49–53
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Inoue, Y., Nakamura, H., Akaji, H. et al. Indirect portography enhanced by nicardipine versus prostaglandin E1 . Cardiovasc Intervent Radiol 18, 92–96 (1995). https://doi.org/10.1007/BF02807229
Issue Date:
DOI: https://doi.org/10.1007/BF02807229